AnTix Holdings（IMTH）株式概要Innovative MedTech, Inc.はその子会社を通じて、米国で健康とウェルネスサービスの提供に従事している。 詳細IMTH ファンダメンタル分析スノーフレーク・スコア評価4/6将来の成長0/6過去の実績2/6財務の健全性1/6配当金0/6報酬当社が推定した公正価値より99.9%で取引されている 今年は黒字化を達成 リスク分析意味のある時価総額がありません ( $108K )マイナスの株主資本 収益が 100 万ドル未満 ( $0 )株式の流動性は非常に低い +3 さらなるリスクすべてのリスクチェックを見るIMTH Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$0.0015該当なし内在価値ディスカウントEst. Revenue$PastFuture-18m2m2016201920222025202620282031Revenue US$1.7Earnings US$0AdvancedSet Fair ValueView all narrativesAnTix Holdings, Inc. 競合他社Regional Health PropertiesSymbol: OTCPK:RHEPMarket cap: US$4.0mVerisante TechnologySymbol: OTCPK:VRSE.FMarket cap: US$92.3kNewGenIvf GroupSymbol: NasdaqCM:NIVFMarket cap: US$430.7kMedical Care TechnologiesSymbol: OTCPK:MDCEMarket cap: US$650.0k価格と性能株価の高値、安値、推移の概要AnTix Holdings過去の株価現在の株価US$0.001552週高値US$0.1952週安値US$0.0012ベータ-0.941ヶ月の変化-11.76%3ヶ月変化n/a1年変化-98.52%3年間の変化n/a5年間の変化-99.89%IPOからの変化-99.90%最新ニュースお知らせ • Sep 30Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/29/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 16Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 21Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million.Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0.016お知らせ • Nov 13Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/12/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 01Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/30/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.最新情報をもっと見るRecent updatesお知らせ • Sep 30Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/29/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 16Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Dec 21Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million.Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0.016お知らせ • Nov 13Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/12/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Oct 01Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/30/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • May 17Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 14Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/13/2023, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 18Innovative MedTech Announces Formation of Scientific Advisory Board and Appoints Roscoe Moore as Member of the Scientific Advisory BoardInnovative MedTech, Inc. announced the formation of its new scientific advisory board (‘SAB’), which the company anticipates will be comprised of leading experts in healthcare and gerontology. The first member of the company's SAB will be Dr. Roscoe Moore DVM, M.P.H., Ph.D. (‘Dr. Moore’). The Scientific Advisory Board (‘SAB’) is expected to play a crucial role in providing strategic guidance and scientific expertise to the Company as it seeks to provide the quality of care and to expand its services. The SAB will be responsible for reviewing and evaluating scientific research and best practices related to adult day care, identifying emerging trends and opportunities, assist the Company with a legislative agenda and develop strategies and recommendations to expand and improve the quality of care provided by the Company. Dr. Moore served as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC), and as an Assistant United States Surgeon General under three Presidential Administrations, and served as the U.S. Chief Veterinary Medical Officer appointed by former U.S. Surgeon General C. Everett Koop. He has also served as a Senior Epidemiologist for the United States Department of Health and Human Services (HHS), and as the Chief Medical Officer of the United States Department of Agriculture's (USDA) Food Safety and Inspection Service. Dr. Moore served in the Office of the US Secretary of Health and Human Services, held the position of Associate Director for Development Support and African Affairs for the Department of Health and Human Services (HHS), and served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA). Dr. Moore is the Founder and President of PH Rockwood LLC. Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, and a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; he also has received an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues. Dr. Moore serves on the Scientific Advisory Board Member of Immgenuity, Inc., Napo Pharmaceuticals, Arev Life Sciences Global Corp, A Legacy Genetics, and Cera Products Incorporated, as well as being a member of the Board of Directors of OyaGen, Inc., a Senior Fellow at Potomac Institute for Policy Studies, and a Board of Advisor Member of the Institute of Human Virology at the University of Maryland School of Medicine.お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2023, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15Innovative MedTech Inc. announced delayed 10-Q filingOn 11/14/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 28Innovative MedTech Inc. announced delayed annual 10-K filingOn 09/27/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jun 16Innovative MedTech Announces Live Version of its RX Vitality App Now Available for Public Download in the Apple iOS App StoreInnovative MedTech Inc. announced that its RX Vitality digital healthcare wallet is now available for download at the Apple iOS App store for Apple iPhone users. The company’s app has already been approved and is available on the Google Play Store. The company is committed to help bank the underbanked, and to help those who need the benefits of its RX Vitality digital wallet. Some of its key app features for qualified members who sign up and are approved for its RX Vitality digital wallet (which will include a healthcare debit card) include: Shop & Earn store, with discounts at 500+ online merchants; Loyalty Program where members can earn points when they shop and use their wallet (or debit card); Certain pharmaceutical discounts of up to 20% to 75% at 65,000 pharmacies across the United States, including Walgreens and CVS.お知らせ • Jun 02Innovative Medtech Appoints Merle Griff as Chief Executive OfficerInnovative MedTech Inc. announced that its Board of Directors has appointed Dr. Merle Griff, who is currently the Chief Executive Officer of the Company’s SarahCare subsidiary, as the Company’s new Chief Executive Officer. She will succeed Michael Friedman, who will remain President of the Company and a member of its Board of Directors. Dr. Griff is a highly respected CEO and industry veteran with 35+ years of leadership experience, including founding and managing SarahCare, the Company’s wholly owned subsidiary. Dr. Griff, is the Founder and CEO of SarahCare Senior Solutions, and is one of the leading authorities on the care of seniors in the United States. Dr. Griff has served on numerous national boards and task forces including being the past Chairperson of the Board of Directors for NADSA (National Adult Day Services Association), member of the International Advisory Board for CARF (Commission on the Accreditation for Rehabilitation Facilities) and a task force member for the study of adult day care in the US for the Assistant Secretary of Program and Evaluation in the Department of Aging.お知らせ • May 28Innovative MedTech Inc. Announces Chief Executive Officer ChangeOn May 24, 2022, Michael Friedman resigned as the Chief Executive Officer of Innovative MedTec Inc. (the Company), and the Board of Directors of the Company appointed Merle Griff, Ph.D. the Chief Executive Officer of the Company. Mr. Friedman will remain the President of the Company as well as member of the Company's Board of Directors. Merle Griff, Ph.D., age 73, is the Founder and has been the CEO of SarahCare (a wholly owned subsidiary of the Company) since its inception approximately 35 years ago.お知らせ • May 17Innovative MedTech Inc. announced delayed 10-Q filingOn 05/16/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • May 12Innovative MedTech Inc. Announces Appointment of David Webb to Company's Advisory BoardInnovative MedTech Inc. announced the appointment of David Webb to the Company’s external advisory board to provide advice and guidance to facilitate growth and innovation at the Company. David has been entertaining and informing the public for more than three decades, from music to talk radio, in Boston, Houston, Dallas, New York City, syndication, now satellite radio and television. Currently, David hosts “The David Webb Show” on SiriusXM Patriot 125 with breaking news, analysis, and commentary.お知らせ • May 06Innovative MedTech Inc. Appoints Bruce Mcdermott to the Company’s External Advisory BoardInnovative MedTech Inc. announced the appointment of Bruce McDermott to the Company’s external advisory board (the “Board”) to provide advice and guidance to facilitate growth and innovation at the Company. Mr. McDermott was one of the sellers of RX Vitality Inc., which the Company acquired on or about April 28, 2022. Mr. McDermott has nearly 40 years of investment and private banking experience originating and financing new opportunities. Mr. McDermott spent most of his career at Deutsche Bank and predecessor companies Bankers Trust and Alex, Brown & Sons. Mr. McDermott led Product Management and Solutions for the Deutsche Bank Private Wealth Management in the Americas.お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2022, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Sep 29Innovative MedTech Inc. announced delayed annual 10-K filingOn 09/27/2021, Innovative MedTech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.株主還元IMTHUS HealthcareUS 市場7D0%-1.2%-1.8%1Y-98.5%19.8%23.3%株主還元を見る業界別リターン: IMTH過去 1 年間で19.8 % の収益を上げたUS Healthcare業界を下回りました。リターン対市場: IMTHは、過去 1 年間で23.3 % のリターンを上げたUS市場を下回りました。価格変動Is IMTH's price volatile compared to industry and market?IMTH volatilityIMTH Average Weekly Movementn/aHealthcare Industry Average Movement7.0%Market Average Movement7.3%10% most volatile stocks in US Market16.8%10% least volatile stocks in US Market3.1%安定した株価: IMTHの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のIMTHのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20051Michael Friedmaninnovativemedtechinc.comInnovative MedTech, Inc.は、その子会社を通じて、米国で健康と福祉サービスの提供に従事している。同社は成人デイケアセンターのプロバイダーおよびフランチャイザーとして運営されている。また、高齢者の身体的・医療的ニーズのモニタリングと対処、看護ケア、サロンサービス、食事、その他の魅力的なアクティビティサービスを含む日中のケアとアクティビティを提供している。同社は以前はフレッシュ・ハーベスト・プロダクツ社として知られていたが、2021年3月にイノベーティブ・メドテック社に社名を変更した。イノベーティブ・メドテック社は2005年に法人化され、イリノイ州ブルーアイランドに本社を置いている。もっと見るAnTix Holdings, Inc. 基礎のまとめAnTix Holdings の収益と売上を時価総額と比較するとどうか。IMTH 基礎統計学時価総額US$108.15k収益（TTM）US$1.18m売上高(TTM)n/a0.1xPER（株価収益率0.0xP/SレシオIMTH は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計IMTH 損益計算書（TTM）収益US$0売上原価US$0売上総利益US$0その他の費用-US$1.18m収益US$1.18m直近の収益報告Jun 30, 2025次回決算日該当なし一株当たり利益（EPS）0.016グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率-61.7%IMTH の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/21 09:02終値2026/06/02 00:00収益2025/06/30年間収益2025/06/30データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋AnTix Holdings, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Sep 30Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/29/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 16Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 21Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million.Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0.016
お知らせ • Nov 13Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/12/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 01Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/30/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Sep 30Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/29/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 16Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2025, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Dec 21Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million.Innovative MedTech, Inc. has filed a Follow-on Equity Offering in the amount of $3.2 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 16,000,000 Price\Range: $0.05 to $0.2 Discount Per Security: $0.016
お知らせ • Nov 13Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/12/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Oct 01Innovative MedTech, Inc. announced delayed annual 10-K filingOn 09/30/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • May 17Innovative MedTech, Inc. announced delayed 10-Q filingOn 05/15/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2024, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 14Innovative MedTech, Inc. announced delayed 10-Q filingOn 11/13/2023, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 18Innovative MedTech Announces Formation of Scientific Advisory Board and Appoints Roscoe Moore as Member of the Scientific Advisory BoardInnovative MedTech, Inc. announced the formation of its new scientific advisory board (‘SAB’), which the company anticipates will be comprised of leading experts in healthcare and gerontology. The first member of the company's SAB will be Dr. Roscoe Moore DVM, M.P.H., Ph.D. (‘Dr. Moore’). The Scientific Advisory Board (‘SAB’) is expected to play a crucial role in providing strategic guidance and scientific expertise to the Company as it seeks to provide the quality of care and to expand its services. The SAB will be responsible for reviewing and evaluating scientific research and best practices related to adult day care, identifying emerging trends and opportunities, assist the Company with a legislative agenda and develop strategies and recommendations to expand and improve the quality of care provided by the Company. Dr. Moore served as an Epidemic Intelligence Service Officer with the Centers for Disease Control and Prevention (CDC), and as an Assistant United States Surgeon General under three Presidential Administrations, and served as the U.S. Chief Veterinary Medical Officer appointed by former U.S. Surgeon General C. Everett Koop. He has also served as a Senior Epidemiologist for the United States Department of Health and Human Services (HHS), and as the Chief Medical Officer of the United States Department of Agriculture's (USDA) Food Safety and Inspection Service. Dr. Moore served in the Office of the US Secretary of Health and Human Services, held the position of Associate Director for Development Support and African Affairs for the Department of Health and Human Services (HHS), and served as the chief epidemiologist with the Centers of Devices and Radiological Health in the US Food and Drug Administration (FDA). Dr. Moore is the Founder and President of PH Rockwood LLC. Dr. Moore has a Ph.D. in Epidemiology from The Johns Hopkins University, an M.P.H. in Epidemiology from the University of Michigan, and a Doctor of Veterinary Medicine and a B.S. degree from Tuskegee Institute; he also has received an honorary D.Sc. degree from Tuskegee University in recognition of his distinguished public health career. Dr. Moore has written or co-authored over 100 publications covering a broad range of public health issues. Dr. Moore serves on the Scientific Advisory Board Member of Immgenuity, Inc., Napo Pharmaceuticals, Arev Life Sciences Global Corp, A Legacy Genetics, and Cera Products Incorporated, as well as being a member of the Board of Directors of OyaGen, Inc., a Senior Fellow at Potomac Institute for Policy Studies, and a Board of Advisor Member of the Institute of Human Virology at the University of Maryland School of Medicine.
お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2023, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15Innovative MedTech Inc. announced delayed 10-Q filingOn 11/14/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 28Innovative MedTech Inc. announced delayed annual 10-K filingOn 09/27/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jun 16Innovative MedTech Announces Live Version of its RX Vitality App Now Available for Public Download in the Apple iOS App StoreInnovative MedTech Inc. announced that its RX Vitality digital healthcare wallet is now available for download at the Apple iOS App store for Apple iPhone users. The company’s app has already been approved and is available on the Google Play Store. The company is committed to help bank the underbanked, and to help those who need the benefits of its RX Vitality digital wallet. Some of its key app features for qualified members who sign up and are approved for its RX Vitality digital wallet (which will include a healthcare debit card) include: Shop & Earn store, with discounts at 500+ online merchants; Loyalty Program where members can earn points when they shop and use their wallet (or debit card); Certain pharmaceutical discounts of up to 20% to 75% at 65,000 pharmacies across the United States, including Walgreens and CVS.
お知らせ • Jun 02Innovative Medtech Appoints Merle Griff as Chief Executive OfficerInnovative MedTech Inc. announced that its Board of Directors has appointed Dr. Merle Griff, who is currently the Chief Executive Officer of the Company’s SarahCare subsidiary, as the Company’s new Chief Executive Officer. She will succeed Michael Friedman, who will remain President of the Company and a member of its Board of Directors. Dr. Griff is a highly respected CEO and industry veteran with 35+ years of leadership experience, including founding and managing SarahCare, the Company’s wholly owned subsidiary. Dr. Griff, is the Founder and CEO of SarahCare Senior Solutions, and is one of the leading authorities on the care of seniors in the United States. Dr. Griff has served on numerous national boards and task forces including being the past Chairperson of the Board of Directors for NADSA (National Adult Day Services Association), member of the International Advisory Board for CARF (Commission on the Accreditation for Rehabilitation Facilities) and a task force member for the study of adult day care in the US for the Assistant Secretary of Program and Evaluation in the Department of Aging.
お知らせ • May 28Innovative MedTech Inc. Announces Chief Executive Officer ChangeOn May 24, 2022, Michael Friedman resigned as the Chief Executive Officer of Innovative MedTec Inc. (the Company), and the Board of Directors of the Company appointed Merle Griff, Ph.D. the Chief Executive Officer of the Company. Mr. Friedman will remain the President of the Company as well as member of the Company's Board of Directors. Merle Griff, Ph.D., age 73, is the Founder and has been the CEO of SarahCare (a wholly owned subsidiary of the Company) since its inception approximately 35 years ago.
お知らせ • May 17Innovative MedTech Inc. announced delayed 10-Q filingOn 05/16/2022, Innovative MedTech Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • May 12Innovative MedTech Inc. Announces Appointment of David Webb to Company's Advisory BoardInnovative MedTech Inc. announced the appointment of David Webb to the Company’s external advisory board to provide advice and guidance to facilitate growth and innovation at the Company. David has been entertaining and informing the public for more than three decades, from music to talk radio, in Boston, Houston, Dallas, New York City, syndication, now satellite radio and television. Currently, David hosts “The David Webb Show” on SiriusXM Patriot 125 with breaking news, analysis, and commentary.
お知らせ • May 06Innovative MedTech Inc. Appoints Bruce Mcdermott to the Company’s External Advisory BoardInnovative MedTech Inc. announced the appointment of Bruce McDermott to the Company’s external advisory board (the “Board”) to provide advice and guidance to facilitate growth and innovation at the Company. Mr. McDermott was one of the sellers of RX Vitality Inc., which the Company acquired on or about April 28, 2022. Mr. McDermott has nearly 40 years of investment and private banking experience originating and financing new opportunities. Mr. McDermott spent most of his career at Deutsche Bank and predecessor companies Bankers Trust and Alex, Brown & Sons. Mr. McDermott led Product Management and Solutions for the Deutsche Bank Private Wealth Management in the Americas.
お知らせ • Feb 15Innovative MedTech, Inc. announced delayed 10-Q filingOn 02/14/2022, Innovative MedTech, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Sep 29Innovative MedTech Inc. announced delayed annual 10-K filingOn 09/27/2021, Innovative MedTech Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
